Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 4/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7017753 | 0.77 | CHRM2 (0.42) | ALDH1A1KDM4ESMN1; SMN2HPGDLMNA | |
| SCHEMBL2913307 | 0.76 | TMEM97 (0.60) | LMNATDP1NPC1RAB9AMAPT | |
| SCHEMBL19674850 | 0.75 | HRH4 (0.43) | ALDH1A1KDM4ESMN1; SMN2HPGDLMNA | |
| SCHEMBL19504487 | 0.74 | HRH3 (0.40) | ALDH1A1KDM4ESMN1; SMN2HPGDLMNA | |
| SCHEMBL17624437 | 0.70 | HRH4 (0.46) | ALDH1A1KDM4ESMN1; SMN2HPGDLMNA | |
| SCHEMBL4009586 | 0.69 | HTR2C (0.63) | ALDH1A1KDM4ETDP1HTTGAA | |
| SCHEMBL8203593 | 0.69 | ALDH1A1 (0.45) | ALDH1A1KDM4ESMN1; SMN2HPGDLMNA | |
| SCHEMBL2793637 | 0.68 | ALDH1A1 (0.67) | ALDH1A1KDM4EHSP90AA1TSHRL3MBTL1 | |
| SCHEMBL2911347 | 0.68 | HTR2C (0.54) | SMN1; SMN2HTTGAAHTR2AHTR2C | |
| SCHEMBL19498194 | 0.67 | GAA (0.43) | ALDH1A1KDM4ESMN1; SMN2HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6653302-B2 | Benign prostatic hyperplasia | PFIZER INC. | 2003-11-25 | — | — | US | disclosed |
| US-20030130259-A1 | Quinoline and quinazoline compounds useful in therapy | FOX DAVID NATHAN ABRAHAM (GB) | 2003-07-10 | — | — | US | disclosed |
| EP-0968208-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | PFIZER LTD (GB) | 2003-06-04 | — | — | EP | disclosed |
| US-6521629-B2 | 2-amine substituted quinoline or quinozoline derivatives useful for treating benign prostatic hyperplasia | PFIZER INC. | 2003-02-18 | — | — | US | disclosed |
| US-20020040028-A1 | Quinoline and quinazoline compounds useful in therapy | FOX DAVID NATHAN ABRAHAM (GB) | 2002-04-04 | — | — | US | disclosed |
| US-6365599-B1 | FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA | PFIZER, INC. | 2002-04-02 | — | — | US | disclosed |
| US-6169093-B1 | FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | PFIZER INC. | 2001-01-02 | — | — | US | disclosed |
| EP-0968208-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | Pfizer Limited (GB) | 2000-01-05 | — | — | EP | disclosed |
| WO-1998030560-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BEGNIN PROSTATIC HYPERPLASIA | PFIZER LIMITED (GB) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130259-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, LPXN | ALDH1A1 498/4885KDM4E 2897/4885SMN1; SMN2 3889/4885 |
| US-20020040028-A1 | Quinoline and quinazoline compounds useful in therapy | BPHL, LPXN, NQO2 | ALDH1A1 420/4885KDM4E 2920/4885SMN1; SMN2 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.